COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments
- 18 November 2020
- journal article
- review article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 27 (14) , 2126-2136
Abstract
The CoronaVirus Disease 19 (COVID-19) pandemic is a threat of particular concern for people affected by chronic immune-mediated diseases, such as multiple sclerosis (MS), who are often treated with immunomodulatory and immunosuppressive drugs, which may increase the risk of infections in general. At the beginning of the COVID-19 pandemic, empirical guidelines on how to manage treatments for immune-mediated diseases, including MS, were released. Subsequently, the first clinical pictures and data sets have been published, describing the outcomes of COVID-19 in patients with MS treated with immunomodulatory and immunosuppressive drugs. Here we will review available information on how infections by human coronaviruses affect the immune system in untreated subjects and in patients affected by MS treated with drugs which modulate the immune system.Keywords
This publication has 52 references indexed in Scilit:
- Pathogenic Influenza Viruses and Coronaviruses Utilize Similar and Contrasting Approaches To Control Interferon-Stimulated Gene ResponsesmBio, 2014
- Noncanonical NF-κB Pathway Controls the Production of Type I Interferons in Antiviral Innate ImmunityImmunity, 2014
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple SclerosisNew England Journal of Medicine, 2012
- B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cellsJournal of Experimental Medicine, 2012
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathwayBrain, 2011
- Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?Annals of Neurology, 2010
- Two‐Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory SyndromeThe Journal of Infectious Diseases, 2006
- Leflunomide for Polyomavirus Type BK NephropathyNew England Journal of Medicine, 2005
- Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirusClinical Microbiology and Infection, 2004
- Plasma inflammatory cytokines and chemokines in severe acute respiratory syndromeClinical and Experimental Immunology, 2004